Abstract
Less than one year into the COVID-19 pandemic, over 70 million individuals worldwide have been infected and case counts continue to accelerate, yet the long-term sequelae of COVID-19 are unknown. We leverage ‘augmented curation’ to extract symptoms and signs occurring post – COVID as noted in follow up physician’s notes of COVID-19 patients at the Mayo Clinic who were diagnosed with SARS-CoV-2 infection between March and September 2020, or influenza between 2014 and 2019. We compare the chart prevalence of signs/symptoms and diseases in the 3-to-6 month post-diagnosis vs. 1-to-6 month pre-diagnosis period for each disease, and subsequently compare the observed effect size of each symptom across the two diseases. Relative to post-influenza, we observe a significant increase in the chart prevalence of terms including “depression”, “anxiety”, “obesity”, and “bleeding” in COVID-19 patients under the age of 55. Across all age groups, “nodules” and “cysts” were also significantly increased. These findings compel targeted investigations into what may be persistent neuropsychiatric, pulmonary, metabolic, and coagulopathic phenotypes following SARS-CoV2 infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding supported this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Mayo Clinic Institutional Review Board as a minimal risk study (IRB 20-003278, 'Study of COVID-19 patient characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions'). Subjects were excluded if they did not have a research authorization on file.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos